https://www.jnj.com/johnson-johnson-announces-single-shot-janssen-covid-19-vaccine-candidate-met-primary-endpoints-in-interim-analysis-of-its-phase-3-ensemble-trial
© 2021 A.T.I. Arzneimittelinformation Berlin GmbH
© 2021 A.T.I. Arzneimittelinformation Berlin GmbH